Literature DB >> 33860172

Predicting Reactions to Psychedelic Drugs: A Systematic Review of States and Traits Related to Acute Drug Effects.

Jacob S Aday1, Alan K Davis2,3, Cayla M Mitzkovitz1, Emily K Bloesch1, Christopher C Davoli1.   

Abstract

Psychedelic drugs are increasingly being incorporated into therapeutic contexts for the purposes of promoting mental health. However, they can also induce adverse reactions in some individuals, and it is difficult to predict before treatment who is likely to experience positive or adverse acute effects. Although consideration of setting and dosage as well as excluding individuals with psychotic predispositions has thus far led to a high degree of safety, it is imperative that researchers develop a more nuanced understanding of how to predict individual reactions. To this end, the current systematic review coalesced the results of 14 studies that included baseline states or traits predictive of the acute effects of psychedelics. Individuals high in the traits of absorption, openness, and acceptance as well as a state of surrender were more likely to have positive and mystical-type experiences, whereas those low in openness and surrender or in preoccupied, apprehensive, or confused psychological states were more likely to experience acute adverse reactions. Participant sex was not a robust predictor of drug effects, but 5-HT2AR binding potential, executive network node diversity, and rACC volume may be potential baseline biomarkers related to acute reactions. Finally, increased age and experience with psychedelics were individual differences related to generally less intense effects, indicating that users may become slightly less sensitive to the effects of the drugs after repeated usage. Although future well-powered, placebo-controlled trials directly comparing the relative importance of these predictors is needed, this review synthesizes the field's current understanding of how to predict acute reactions to psychedelic drugs.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 33860172      PMCID: PMC8033773          DOI: 10.1021/acsptsci.1c00014

Source DB:  PubMed          Journal:  ACS Pharmacol Transl Sci        ISSN: 2575-9108


  63 in total

1.  Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.

Authors:  Roland R Griffiths; Matthew W Johnson; William A Richards; Brian D Richards; Una McCann; Robert Jesse
Journal:  Psychopharmacology (Berl)       Date:  2011-06-15       Impact factor: 4.530

2.  Mystical Experiences in Retrospective Reports of First Times Using a Psychedelic in Finland.

Authors:  Samuli Kangaslampi; Aino Hausen; Tarina Rauteenmaa
Journal:  J Psychoactive Drugs       Date:  2020-06-08

Review 3.  Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.

Authors:  Rafael G Dos Santos; José Carlos Bouso; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2017-02-23

4.  Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Authors:  Theresa M Carbonaro; Matthew P Bradstreet; Frederick S Barrett; Katherine A MacLean; Robert Jesse; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-08-30       Impact factor: 4.153

5.  Brain serotonin 2A receptor binding predicts subjective temporal and mystical effects of psilocybin in healthy humans.

Authors:  Dea Siggaard Stenbæk; Martin Korsbak Madsen; Brice Ozenne; Sara Kristiansen; Daniel Burmester; David Erritzoe; Gitte Moos Knudsen; Patrick MacDonald Fisher
Journal:  J Psychopharmacol       Date:  2020-10-08       Impact factor: 4.153

6.  Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.

Authors:  Roland R Griffiths; Ethan S Hurwitz; Alan K Davis; Matthew W Johnson; Robert Jesse
Journal:  PLoS One       Date:  2019-04-23       Impact factor: 3.240

7.  Predicting Responses to Psychedelics: A Prospective Study.

Authors:  Eline C H M Haijen; Mendel Kaelen; Leor Roseman; Christopher Timmermann; Hannes Kettner; Suzanne Russ; David Nutt; Richard E Daws; Adam D G Hampshire; Romy Lorenz; Robin L Carhart-Harris
Journal:  Front Pharmacol       Date:  2018-11-02       Impact factor: 5.810

8.  Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution.

Authors:  M V Uthaug; K van Oorsouw; K P C Kuypers; M van Boxtel; N J Broers; N L Mason; S W Toennes; J Riba; J G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2018-08-13       Impact factor: 4.530

9.  Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience.

Authors:  Candace R Lewis; Katrin H Preller; B Blair Braden; Cory Riecken; Franz X Vollenweider
Journal:  Biomedicines       Date:  2020-02-18

10.  Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects.

Authors:  Friederike Holze; Patrick Vizeli; Laura Ley; Felix Müller; Patrick Dolder; Melanie Stocker; Urs Duthaler; Nimmy Varghese; Anne Eckert; Stefan Borgwardt; Matthias E Liechti
Journal:  Neuropsychopharmacology       Date:  2020-10-15       Impact factor: 7.853

View more
  15 in total

1.  Selective Serotonin Receptor Modulators for Use in the Treatment of Psychological Disorders.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2022-03-30       Impact factor: 4.345

Review 2.  Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research.

Authors:  David Bender; David J Hellerstein
Journal:  Psychopharmacology (Berl)       Date:  2022-01-13       Impact factor: 4.530

3.  The Psychedelic Renaissance: Addressing Potential Adverse Effects in a Therapeutic Setting.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2021-11-08       Impact factor: 4.345

4.  Improved 5-HT2 Selective Receptor Modulators for the Treatment of Psychological Disorders.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2021-11-08       Impact factor: 4.345

5.  Psilocin Derivatives as Serotonergic Psychedelic Agents for the Treatment of CNS Disorders.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2021-09-12       Impact factor: 4.632

6.  Psychedelic Therapeutic: Potential Treatment for Headache Disorders.

Authors:  Robert B Kargbo
Journal:  ACS Med Chem Lett       Date:  2021-09-28       Impact factor: 4.632

Review 7.  Psychedelics and Other Psychoplastogens for Treating Mental Illness.

Authors:  Maxemiliano V Vargas; Retsina Meyer; Arabo A Avanes; Mark Rus; David E Olson
Journal:  Front Psychiatry       Date:  2021-10-04       Impact factor: 4.157

8.  Psilocybin-Induced Mystical-Type Experiences are Related to Persisting Positive Effects: A Quantitative and Qualitative Report.

Authors:  Drummond E-Wen McCulloch; Maria Zofia Grzywacz; Martin Korsbak Madsen; Peter Steen Jensen; Brice Ozenne; Sophia Armand; Gitte Moos Knudsen; Patrick MacDonald Fisher; Dea Siggaard Stenbæk
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

9.  The Acceptance/Avoidance-Promoting Experiences Questionnaire (APEQ): A theory-based approach to psychedelic drugs' effects on psychological flexibility.

Authors:  Max Wolff; Lea J Mertens; Marie Walter; Sören Enge; Ricarda Evens
Journal:  J Psychopharmacol       Date:  2022-03       Impact factor: 4.153

Review 10.  Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT.

Authors:  Steven A Barker
Journal:  Psychopharmacology (Berl)       Date:  2022-01-22       Impact factor: 4.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.